|
|
Blood, 1 August 2008, Vol. 112, No. 3, pp. 603-609.
Prepublished online as a Blood First Edition Paper on May 16, 2008; DOI 10.1182/blood-2008-02-142943.
Previous Article | Next Article 
Submitted February 29, 2008
Accepted April 28, 2008
Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIA
Isabelle Marx, Olivier D Christophe, Peter J. Lenting, Alain Rupin, Marie-Odile Vallez, Tony J Verbeuren, and Cecile V Denis*
Institut National de la Sante et de la Recherche Medicale U770, INSERM, Le Kremlin-Bicetre, France
Laboratory for Thrombosis and Haemostasis, Department of Clinical Chemistry & Haematology, University Medical Center Utrecht, Utrecht, Netherlands
Division of Angiology, SERVIER Research Institute, Suresnes, France
* Corresponding author; email: cecile.denis{at}inserm.fr.
Von Willebrand factor (VWF) role in thrombosis involves its binding to a number of ligands. To investigate the relative importance of these particular interactions in the thrombosis process, we have introduced mutations into murine VWF (mVWF) cDNA inhibiting VWF binding to glycoprotein (Gp) Ib, GpIIbIIIa, or to fibrillar collagen. These VWF mutants were expressed in VWF deficient mice (VWF-/-) by using the hydrodynamic injection approach and the mice were studied in the ferric chloride-induced injury model. Expression of the collagen and the GPIIbIIIa VWF binding mutants in VWF-/- mice resulted in delayed thrombus growth and significantly increased vessel occlusion times compared to mice expressing wild-type (WT) mVWF (30±3 min and 38±4 min for the collagen and GPIIbIIIa mutants, respectively, versus 19±3 min for WT mVWF). Interestingly, these mutants were able to correct bleeding time as efficiently as WT mVWF. In contrast, VWF-/- mice expressing the GPIb binding mutant failed to restore thrombus formation and were bleeding for as long as they were observed, confirming the critical importance of the VWF-GPIb interaction.
Our observations suggest that targeting the VWF-collagen or VWF- GPIIbIIIa interactions could be an interesting alternative for new antithrombotic strategies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Momi, E. Falcinelli, S. Giannini, L. Ruggeri, L. Cecchetti, T. Corazzi, C. Libert, and P. Gresele
Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo
J. Exp. Med.,
October 26, 2009;
206(11):
2365 - 2379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. Riddell, K. Gomez, C. M. Millar, G. Mellars, S. Gill, S. A. Brown, M. Sutherland, M. A. Laffan, and T. A. J. McKinnon
Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor
Blood,
October 15, 2009;
114(16):
3489 - 3496.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. F. De Meyer, H. Deckmyn, and K. Vanhoorelbeke
von Willebrand factor to the rescue
Blood,
May 21, 2009;
113(21):
5049 - 5057.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|